The role of cyclooxygenase selective inihibitors in the gastrointestinal tract

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 453-458

  Cryer, Byron ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; ISOENZYME; KETOROLAC; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; VALDECOXIB; ISOXAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE; SULFONE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG HALF LIFE; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT FUNCTION; HEART INFARCTION; HUMAN; INTESTINE OBSTRUCTION; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH PAIN; STOMACH ULCER; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; DIGESTIVE SYSTEM; DRUG EFFECT; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; HUMANS; ISOXAZOLES; PYRIDINES; SULFONAMIDES; SULFONES; ULCER;

EID: 1542540203     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0033-7     Document Type: Review

References (26)

1. O'Banion MK, Sadowski HB, Winn V, Young DA: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991, 266:23261-23267.
2. Wallace JL, McKnight W, Reuter B, Vergnolle N: NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000, 119:706-714.
3. Riendeau D, Percival MD, Brideau C, et al.: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001, 296:558-566.
4. Lanza FL, Rack MF, Simon TJ, et al.: Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999, 13:761-767.
5. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106-2111.
6. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999, 282:1921-1928.
7. Laine L, Harper S, Simon T, et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999, 117:776-783.
8. Sikes DH, Agrawal NM, Zhao WW, et al.: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002, 14:1101-1111.
9. Langman MJ, Jensen DJ, Watson DJ, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929-1933.
10. Goldstein JL, Silverstein FE, Agrawal NM, et al.: Reduced risk of upper gastrointestinal complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000, 95:1681-1690.
11. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284:1247-1255.
12. Bombardier C, Laine L, Reicin A, et al.: Rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
13. Ray WA, Stein M, Hall K, et al.: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort. Lancet 2002, 359:118-123.
14. Schmassmann A, Peskar BM, Stettler C, et al.: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998, 23:795-804.
15. Mizuno H, Sakamoto C, Matsuda K, et al.: Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by specific antagonists delays healing in mice. Gastroenterology 1997, 112:387-397.
16. Vogiagis D, Glare EM, Misajon A, et al.: Cyclooxygenase-1 and an alternatively spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol 2000, 278:G820-G827.
17. To KF, Chan FKL, Cheng ASL, et al.: Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther 2001, 15:25-34.
18. Talley JJ, Bertenshaw SR, Brown DL, et al.: N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000 43:1661-1663.
19. Malan TP Jr, Marsh G, Hakki SI, et al.: Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003, 98:950-956.
20. Daniels SE, Grossman EH, Kuss ME, et al.: A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001, 23:1018-1031.
21. Harris SI, Kuss M, Hubbard RC, Goldstein JL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001, 23:1422-1428.
22. Agrawal NG, Porras AG, Matthews CZ, et al.: Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003, 43:268-276.
23. Hunt RH, Harper S, Callegari P, et al.: Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003, 17:201-210.
24. Hunt RH, Harper S, Watson DJ, et al.: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003, 98:1725-1733.
25. Tannenbaum H, Berenbaum F, Reginster JY, et al.: Lumiracoxib is effective in the treatment of osteoarthritis of the knee [abstract]. Arthritis Rheum 2002, 46:S336.
26. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.